# HealthTech Arkansas

> HealthTech Arkansas is a VC fund in Little Rock backing Health Care and Medical Device. See 3 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Little Rock, United States
- Total investments: 3
- Last investment: Apr 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/healthtecharkansas
- Website: https://www.healthtecharkansas.com/

HealthTech Arkansas is an investment firm that targets three areas of healthcare innovation digital health, medical devices, and diagnostic platforms. The firm seeks technologies that can improve our providers’ operations by improving the quality of care, enhancing efficiencies, and reducing costs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Medical Device | 2 | 67% |
| Medical | 1 | 33% |
| Software | 1 | 33% |
| Artificial Intelligence | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Non-equity Assistance | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 33% |
| South Korea | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mediwhale | Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $9M | Series A | Apr 18, 2023 |  |
| Acorai | Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Our product, The Acorai Heart Monitor, can monitor mean pulmonary artery pressure (mPAP) non-invasively through a machine learning analysis of pressure dynamics in acoustics,vibratory and waveform data. Our technology show compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement and a fast track to commercialization. With a team with more than 50 years of industry experience, we can help heart failure patients live longer, healthier, and less uncertain lives.Acorai was founded in 2019 and is headquartered in Skane, Sweden. |  | Non-equity Assistance | Nov 24, 2022 |  |
| Acorai | Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Our product, The Acorai Heart Monitor, can monitor mean pulmonary artery pressure (mPAP) non-invasively through a machine learning analysis of pressure dynamics in acoustics,vibratory and waveform data. Our technology show compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement and a fast track to commercialization. With a team with more than 50 years of industry experience, we can help heart failure patients live longer, healthier, and less uncertain lives.Acorai was founded in 2019 and is headquartered in Skane, Sweden. | $1.5M | Seed | Apr 01, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Mayo Clinic](https://shizune.co/investors/profile/mayoclinic) — VC Fund, 2 deals together
- [MedAxiom](https://shizune.co/investors/profile/medaxiom) — VC Fund, 2 deals together
- [Aerion Partners](https://shizune.co/investors/profile/aerion-partners) — VC Fund, 1 deal together
- [Arizona State University](https://shizune.co/investors/profile/arizona-state-university) — VC Fund, 1 deal together
- [BNK Venture Capital](https://shizune.co/investors/profile/bnk-venture-capital) — VC Fund, 1 deal together
- [BNK Venture Capital](https://shizune.co/investors/profile/bnk-venture-capital-c3fd) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does HealthTech Arkansas invest in?

HealthTech Arkansas invests primarily in Health Care, Medical Device and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did HealthTech Arkansas last invest?

The most recent investment recorded for HealthTech Arkansas closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co